KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Non-Current Assets (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Other Non-Current Assets data on record, last reported at $3.7 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 43.08% year-over-year to $3.7 million; the TTM value through Sep 2025 reached $3.7 million, down 43.08%, while the annual FY2024 figure was $18.9 million, N/A changed from the prior year.
  • Other Non-Current Assets reached $3.7 million in Q3 2025 per EBS's latest filing, down from $6.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $194.6 million in Q2 2023 and bottomed at $1.3 million in Q2 2024.
  • Average Other Non-Current Assets over 5 years is $63.9 million, with a median of $51.3 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: soared 375.74% in 2023, then plummeted 99.33% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $57.3 million in 2021, then dropped by 28.8% to $40.8 million in 2022, then skyrocketed by 375.74% to $194.1 million in 2023, then plummeted by 90.26% to $18.9 million in 2024, then crashed by 80.42% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $3.7 million in Q3 2025, $6.1 million in Q2 2025, and $3.7 million in Q1 2025.